Cellenkos has received FDA clearance to launch a phase II trial of CK0801 for aplastic anaemia, targeting patients unresponsive or intolerant to standard treatments. The therapy, developed with the ...
Cellenkos has received the US Food and Drug Administration (FDA) clearance to begin its Phase II clinical trial of CK0801 to ...
Hosted on MSN
Japan launches phase II AML trial of ziftomenib
Kyowa Kirin and Kura Oncology have begun a Phase II registrational trial in Japan for ziftomenib, an oral menin inhibitor, in adults with relapsed or refractory NPM1-mutated acute myeloid leukaemia.
HOUSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Hopstem Biotechnology Inc. (hereinafter referred to as "Hopstem"), a company dedicated to the development of induced pluripotent stem cell (iPSC)-derived ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results